英国制药工业市场前景及投资研究报告-培训课件外文版2024.5疫苗

INDUSTRIES

&

MARKETSPharmaceuticalindustryintheUnitedKingdom(UK)CHAPTER

01InternationalpositioningMarketshareofleading10nationalpharmaceuticalmarketsworldwidein2022Marketshareoftheleadingglobalpharmaceuticalmarkets2022Marketshare20%0%5%10%15%25%30%35%40%45%42.6%UnitedStatesChina*7.6%Japan4.5%GermanyFrance4%2.8%2.4%2.3%2%ItalyUnitedKingdomCanadaSpain1.9%1.9%Brazil**4Description:TheUnitedStateswasthelargestnationalpharmaceuticalmarketin2022,makingupover42percentofthetotalpharmaceuticalspendingworldwide.Chinaisthesecond-largestmarketwithamarketshareofaroundeightpercent(althoughincludingonlythehospitalmakret).ReadmoreNote(s):UnitedStatesSource(s):IQVIAGrowthrateoftop10nationalpharmaceuticalmarketsworldwidein2022Topglobalpharmaceuticalmarkets:growthrate2022Growthrate-5%0%5%10%15%20%Brazil**France17.7%10.3%10%ItalyCanada9.5%9.4%UnitedStatesSpain8%UnitedKingdomGermanyJapan6.3%5.4%2.6%China*-1.9%5Description:In2022,thegrowthrateofBrazil`spharmaceuticalmarketstoodatnearly18percent,whichwassignificanthigherthanofanyotherleadingnationalpharmaceticalmarket.China,ontheotherhand,wastheonlycountryamongthesecountriesshowinganactualdecreaseofthemarket.ReadmoreNote(s):WorldwideSource(s):IQVIAValueofpharmaceuticalproductsimportedintotheUnitedKingdom(UK)fromtheEU-27from2018to2022(inmillionU.S.dollars)UKpharmaceuticalproductsimportvaluefromtheEU2018-202230,00024,57225,00020,00015,00010,0005,000023,42121,12219,97019,002201820192020202120226Description:In2022,theUnitedKingdomimportedaround19billionU.S.billiondollars`worthofpharmaceuticalproductsfromtherestoftheEuropeanUnion.ThisisasignificantdecreasecomparedtoyearsbeforetheBrexitwhenimportswereupto27billiondollars.However,theimpactoftheCOVID-19pandemicmightalsobeacauseforthisdevelopment.ReadmoreNote(s):UnitedKingdom;2018to2022Source(s):OECDValueofpharmaceuticalproductsexportedfromtheUnitedKingdom(UK)totheEU-27from2018to2022(inmillionU.S.dollars)UKpharmaceuticalproductsexportvaluetotheEU2018-202218,00015,60716,00014,00012,00010,0008,0006,0004,0002,000012,88412,12511,85111,235201820192020202120227Description:ThisstatisticdepictstheannualvalueofpharmaceuticalproductsexportedfromtheUnitedKingdom(UK)totheEuropeanUnion's27nations(EU-27)from2016to2022.UKexportsofpharmaceuticalproductstotheEU-27wereworthapproximately12.9billionU.S.dollarsin2022,thehighestvaluesincetheBrexit.ReadmoreNote(s):UnitedKingdom;2018to2022Source(s):OECDPharmaceuticalproductstradebalanceoftheUnitedKingdom(UK)withEU-27countriesin2022(in1,000GBP)UnitedKingdom:pharmaceuticalproducttradebalancewithEU-27bycountry2022TradebalancevalueinthousandGBP-1,400,000

-1,200,000

-1,000,000

-800,000-2,000,000Germany-1,800,000-1,600,000-600,000-400,000-200,0000-1,889,252ItalySpain-1,216,742-812,686Ireland-499,667DenmarkGreece-365,113-263,922-181,790HungaryAustriaSweden-175,283-165,660CzechRepublicPortugalSloveniaCroatia-132,227-80,393-53,261-38,0048Description:ThisstatisticdisplaystheUnitedKingdom'stradebalanceinpharmaceuticalproductswiththecountriesoftheEuropeanUnionin2022.Inthatyear,theUnitedKingdomhadanegativetradebalanceofsome1.9billionBritishpoundswithGermany.TheUKhadanegativepharmaceuticalproductstradebalancewithmostcountriesoftheEU-27.ReadmoreNote(s):UnitedKingdom;2022Source(s):InternationalTradeCentre;UNComtradeCHAPTER

02NationaloverviewRevenueinthemanufactureofbasicpharmaceuticalproductsintheUnitedKingdomfrom2008to2021,bysubdivision(inmillionGBP)RevenueofpharmaceuticalsmanufacturingintheUK2008-2021,bysubdivisionManufactureofbasicpharmaceuticalpreparationsManufactureofbasicpharmaceuticalproducts25,00020,00015,00010,0005,000022,44820,93919,99918,61017,06316,71815,65914,68413,55712,39812,1719,0806,9482,4332,5181,8732,0011,4641,2541,2131,300718200841220091.56201720122013201420152016201820192020202110Description:Thisstatisticdisplaysthetotalrevenueinthemanufactureofpharmaceuticalproductsandpharmaceuticalpreparationsfrom2008to2021,intheUnitedKingdom,byindustrysubdivision.In2021,therevenueinthemanufactureofbasicpharmaceuticalpreparationswasaround22.5billionBritishpounds.ReadmoreNote(s):UnitedKingdom;2008to2021Source(s):OfficeforNationalStatistics(UK)RevenueofpharmaceuticalpreparationsandproductsmanufacturingintheUnitedKingdomfrom2008to2021(inmillionGBP)RevenueofpharmaceuticalproductsmanufacturingintheUK2008-202130,00025,00024,96623,37222,00020,48320,00015,00010,0005,000018,71618,36318,27317,24816,07116,02715,40215,02113,65213,3852008200920102011201220132014201520162017201820192020202111Description:Thisstatisticdisplaysthetotalrevenueofmanufactureofbasicpharmaceuticalproductsandpreparationsfrom2008to2021intheUnitedKingdom.Intheyear2021,thetotalrevenueofthemanufactureofpharmaceuticalproductsandpreparationsstoodatnearly25billionBritishpounds,thehighestvalueintheprovidedtimeinterval.ReadmoreNote(s):UnitedKingdom;2008to2021Source(s):OfficeforNationalStatistics(UK)LeadingchemicalsubstancesdispensedinEnglandin2022,bynumberofitemsTopchemicalsubstancesdispensedinEngland2022,byitemnumberNumberofitems20,000,000

30,000,000010,000,00040,000,00050,000,00060,000,00057,050,843AtorvastatinOmeprazole35,414,270Amlodipine34,376,10133,439,343LevothyroxinesodiumLansoprazole32,474,088Ramipril31,393,74527,384,47625,706,87924,139,69121,745,810BisoprololfumarateColecalciferolMetforminhydrochlorideSertralinehydrochloride12Description:AtorvastatinwasthetopdispensedchemicaldruginEnglandin2022withmorethan57millionitemssupplied.ThisdrugisonlyavailableviaaprescriptionintheUnitedKingdomandisusedtolowerthecholesterolofindividualswhosufferfromhighcholesterol.Thus,reducingtheriskofheartattacksandstrokesintheprocess.Thethirdmostdispenseddruginthisyearwaslevothyroxinesodiumwhichisusedtotreatthosewithanunderactivethyroidgland,otherwiseknownas[...]

ReadmoreNote(s):UnitedKingdom(England);2022Source(s):NHSBSALeading10analgesicdrugsdispensedinEnglandin2022,bynumberofitemsLeading10analgesicdrugsdispensedinEngland2022,byitemNumberofitems02,000,000

4,000,000

6,000,000

8,000,000

10,000,000

12,000,000

14,000,000

16,000,000

18,000,000ParacetamolCo-codamol(Codeinephosphate/paracetamol)Tramadolhydrochloride16,168,04515,115,2495,660,406Codeinephosphate5,187,329Morphinesulfate5,111,163Buprenorphine2,505,4982,172,025SumatriptansuccinateOxycodonehydrochloride1,835,165Dihydrocodeinetartrate1,463,066Co-dydramol(Dihydrocodeine/paracetamol)1,431,04113Description:ThisstatisticdisplaystheleadingtenanalgesicdrugsdispensedinEnglandin2022,bynumberofprescriptionitems.Inthatyear,therewereapproximately16.2millionitemsofparacetamoldispensedinthecountry.ReadmoreNote(s):UnitedKingdom(England);2022Source(s):NHSBSAConsumerpriceindex(CPI)ofpharmaceuticalproductsannuallyintheUnitedKingdom(UK)from2003to2022Pharmaceuticalproductsconsumerpriceindex(CPI)annuallyintheUK2003-2022120114112.1

111.6108.6106.3103.9101.810098.3961008060402009593.290.690.888.788.488.987.687.287.32003

2004

2005

2006

2007

2008

2009

2010

2011

2012

2013

2014

2015

2016

2017

2018

2019

2020

2021

202214Description:In2022,theconsumerpriceindex(CPI)ofpharmaceuticalproductsintheUnitedKingdom(UK)wasmeasuredat114.TheCPIisdesignedtomeasurechangesinthepricesofgoodsthatconsumersbuy.2015isusedasthebaseyearforcalculationsandthereforetheindexinthisyearmeasures100.ReadmoreNote(s):UnitedKingdom;2003to2022Source(s):OfficeforNationalStatistics(UK)ResearchanddevelopmentexpenditureofpharmaceuticalbusinessesintheUnitedKingdom(UK)from2002to2021(inmillionGBP)UKpharmaceuticalbusinesses:R&Dexpenditure2002-20219,0008,0007,0008,2006,0005,0174,9144,7335,0004,0003,0002,0001,00004,6734,4244,4154,3544,3204,2084,1654,0904,0393,9353,8553,5213,3743,2393,169

3,1272002

2003

2004

2005

2006

2007

2008

2009

2010

2011

2012

2013

2014

2015

2016

2017

2018

2019

2020

2021*15Description:ThisstatisticshowsexpenditureonresearchanddevelopmentbyUKbusinessesoperatinginthepharmaceuticalindustryfrom2002to2021.In2020,expenditureonR&DamountedtoapproximatelyfivebillionBritishpounds,anincreasefromthepreviousyear.ReadmoreNote(s):UnitedKingdom;2002to2021;businessesknowntoperformR&DSource(s):OfficeforNationalStatistics(UK)CHAPTER

03CompanylandscapeLeadingpharmaceuticalandbiotechnologycompaniesintheUnitedKingdom(UK)asof2023,basedonmarketcapitalization(inbillionGBP)LeadingUKpharmaceuticalandbiotechnologycompaniesrankedbymarketvalue2023MarketvalueinbillionGBP020406080100120140160180168.33AstraZenecaGlaxoSmithklineHaleon61.7831.37HikmaPharmaceuticalsDechraPharmaceuticalsIndivior4.464.322.26OxfordNanoporeGenus1.591.4Ergomed

0.68PureTechHealth

0.517Description:ThisstatisticshowstheleadingpharmaceuticalandbiotechnologycompaniesoriginatedfromtheUnitedKingdom(UK),asoflate2023,basedonmarketcapitalization.AsofOctoberofthatyear,GlaxoSmithKline(GSK)rankedsecondhighestonthelistwithamarketcapitalizationofsome62billionBritishpounds.FirstwasBritish-SwedishfirmAstraZenecawithamarketcapitalizationofaround168billionBritishpounds.ReadmoreNote(s):UnitedKingdom;asofOctober19,2023Source(s):ThomsonReuters;Varioussources(companydata)AstraZeneca'srevenuefrom2006to2022(inmillionU.S.dollars)AstraZeneca'srevenue2006-202250,00045,00040,00042,99836,54133,59133,26935,00030,00025,00020,00015,00010,0005,000032,80431,60129,55927,97326,47526,09525,89025,71123,64123,56521,31921,04920,1522006200720082009201020112012201320142015201620172018201920202021202218Description:ThisstatisticshowstherevenueofpharmaceuticalcompanyAstraZenecafrom2006to2022.AstraZenecaplcisoneofthetop10pharmaceuticalcompaniesworldwide(basedonRxdrugrevenue).ThemultinationalcompanyisheadquarteredinLondon,UK.AstraZenecaisfocusedonproductsforfollowingmajordiseaseareas:cancer,cardiovascular,gastrointestinal,infection,neuroscience,respiratoryandinflammation.TogetherwiththeOxfordUniversity,thecompanyalsodeveloped[...]

ReadmoreNote(s):WorldwideSource(s):AstraZenecaAstraZeneca'srevenuefrom2020to2022,bytherapyarea(inmillionU.S.dollars)AstraZeneca'srevenuebytherapeuticarea2020-202220202021202216,00014,63114,00012,00010,0008,0006,0004,0002,000012,94010,8129,1888,0887,0967,0536,0345,7655,3574,665

4,7363,1101,9181,704

1,62566938RarediseasesOncologyCardiovascular,renalandmetabolicdiseasesRespiratory&immunologyVaccines&immunetherapiesOtherdiseaseareas19Description:ThisstatisticshowstherevenueofpharmaceuticalcompanyAstraZenecabytherapyareafrom2020to2022.In2022,revenueintheareaofoncologyamountedto14.6billionU.S.dollars.AstraZenecaplcisaleadingpharmaceuticalcompaniesworldwide.ThemultinationalcompanyisheadquarteredinLondon,UK.AstraZenecaisfocusedonproductsforfollowingmajordiseaseareas:cancer,cardiovascular,gastrointestinal,infection,neuroscience,respiratoryandinflammation.

ReadmoreNote(s):WorldwideSource(s):AstraZenecaGSK'srevenuefrom2006to2022(inmillionBritishpounds)GSK'srevenue2006-202240,00034,099

34,11433,75435,00030,00025,00020,00015,00010,0005,000030,82130,18629,32428,368

28,39227,88927,38726,431

26,50524,35023,92323,23023,00622,72020062007200820092010201120122013201420152016201720182019202020212022*20Description:ThisstatisticdepictstherevenueofpharmaceuticalcompanyGSK(GlaxoSmithKline)from2006to2022.GlaxoSmithKlineplcisoneoftheleadingpharmaceuticalcompaniesworldwide.ThemultinationalcompanyisheadquarteredinLondon,UK.In2022,thecompanygeneratedatotalofsome29.3billionBritishpoundsofrevenue,comparedto34.1billionin2021.ThelowerrevenuefigurereflectsthedemergerofGSK'sConsumerHealthcarebusinessinmid-2022.

ReadmoreNote(s):WorldwideSource(s):GlaxoSmithKlineGSK'spharmaceuticalsrevenuein2022,bytherapeuticarea(inmillionBritishpounds)GSKpharmaceuticalsrevenuebytherapeuticarea20227,0006,0005,0004,0003,0002,0001,00006,5485,7493,5703,0852,9582,6092,3091,1167146026421Description:ThestatisticshowsGSK's(GlaxoSmithKline)pharmaceuticalsrevenuesin2022,bytherapeuticarea.GSKplcisoneofthelargestpharmaceuticalcompaniesworldwide.ThemultinationalcompanyisheadquarteredinLondon,UK.In2022,thecompanygeneratedsome6.5billionBritishpoundsofrevenuewithrespiratoryproducts.ReadmoreNote(s):WorldwideSource(s):GlaxoSmithKlineNumberofenterprisesforthemanufactureofpharmaceuticalproductsandpreparationsintheUnitedKingdomfrom2008to2021EnterprisesinmanufactureofpharmaproductsandpreparationsUK2008-202180070069169066664663661057360050040030020010005355295104654444483762008200920102011201220132014201520162017201820192020202122Description:Thisstatisticdisplaysthenumberofenterprisesinthemanufactureofpharmaceuticalproductsandpharmaceuticalpreparationsfrom2008to2021,intheUnitedKingdom.In2021,therewere690enterprisesinthemanufactureofpharmaceuticalproductsandpreparations,thesecondhighestamountintheprovidedtimeinterval.ReadmoreNote(s):UnitedKingdom;2008to2021Source(s):OfficeforNationalStatistics(UK)NumberofenterprisesinthemanufactureofbasicpharmaceuticalproductsintheUnitedKingdomfrom2008to2021,bysubdivisionEnterprisesinpharmaceuticalsmanufacturingintheUK2008-2021,bysubdivisionManufactureofbasicpharmaceuticalpreparationsManufactureofbasicpharmaceuticalproducts80070060050040030020010002452372061941881831681801781791101231451154604534484524464274053553513553313213032612008200920102011201220132014201520162017201820192020202123Description:ThisstatisticdisplaysthetotalnumberofenterprisesinthemanufactureofpharmaceuticalproductsandpharmaceuticalpreparationsintheUnitedKingdomfrom2008to2021,byindustrialsubdivision.In2021,therewere453enterprisesinvolvedinthemanufactureofbasicpharmaceuticalpreparations.ReadmoreNote(s):UnitedKingdom;2008to2021Source(s):OfficeforNationalStatistics(UK)NumberofenterprisesforthewholesaleofpharmaceuticalgoodsintheUnitedKingdom(UK)from2008to2021NumberofpharmaceuticalgoodswholesalersintheUnitedKingdom(UK)2008-20213,5002,9782,9883,0002,7512,7322,7092,6812,6202,4702,3772,5002,0001,5001,0005002,2052,1562,1082,0872,08002008200920102011201220132014201520162017201820192020202124Description:In2021,therewerenearlythreethousandwholesalersofpharmaceuticalgoodsintheUnitedKingdom.Thenumberofenterprisesforthewholesaleofpharmaceuticalgoodshassignificantlyincreasedinthecountrysince2008.

ReadmoreNote(s):UnitedKingdom;2008to2021Source(s):OfficeforNationalStatistics(UK)CHAPTER

04FinancialimpactConsumerexpenditureonpharmaceuticalproductsintheUnitedKingdom(UK)from2005to2022(inmillionGBP)ExpenditureonpharmaceuticalproductsintheUnitedKingdom2005-202210,0009,0008,0008,6118,5947,9887,8627,7927,4677,3127,3157,1127,0137,0006,0005,0004,0003,0002,0001,00005,1623,77820073,7883,62820103,23620082,53520091,77120051,300200620112012201320142015201620172018201920202021202226Description:ConsumersintheUnitedKingdom(UK)spentapproximatelyeightbillionBritishpoundsonpharmaceuticalproductsin2022.Since2005consumerspendinginthismarkethasincreasedalmostfivefoldintheprovidedtimeinterval.However,therewasadecreasefrom2021to2022.ReadmoreNote(s):UnitedKingdom;2005to2022Source(s):OfficeforNationalStatistics(UK)Approximategrossvalueadded(aGVA)ofpharmaceuticalproductsandpreparationsmanufacturingintheUKfrom2008to2021(inmillionGBP)Pharmaceuticalmanufacturinggrossvalueadded(aGVA)inUK2008-202112,0009,62910,0008,0006,0004,0002,00009,4558,9388,8438,5698,2397,8247,8767,5667,4176,7366,3345,6635,3452008200920102011201220132014201520162017201820192020202127Description:Thisstatisticdisplaystheapproximategrossvalueadded(aGVA)atbasicpricesofthemanufactureofpharmaceuticalproductsandpharmaceuticalpreparationsfrom2008to2021,intheUnitedKingdom.In2021,theaGVAofpharmaceuticalmanufacturingstoodatsome8.2billionBritishpounds,asignificantdropcomparedtotheprecedingyear.ReadmoreNote(s):UnitedKingdom;2008to2021Source(s):OfficeforNationalStatistics(UK)Approximategrossvalueadded(aGVA)ofpharmaceuticalmanufacturingintheUnitedKingdomfrom2008to2021,byindustrysubdivision(inmillionGBP)PharmaceuticalmanufacturinggrossvalueaddedintheUK2008-2021,bysubdivisionManufactureofbasicpharmaceuticalpreparationsManufactureofbasicpharmaceuticalproducts8,3719,0008,0007,0006,0005,0004,0003,0002,0001,00008,4748,2858,0687,6707,4927,3097,2215,7185,0784,8634,3072,42998174761658565565348247150125720081542009201220132014201520162017201820192020202128Description:Thisstatisticdisplaystheapproximategrossvalueaddedatbasicprices(aGVA)ofthemanufactureofpharmaceuticalproductsandpharmaceuticalpreparationsintheUnitedKingdomfrom2008to2021,byindustrysubdivision.TheaGVAofbasicpreparationsmanufacturingin2021amountedtoaround7.5billionBritishpounds.ReadmoreNote(s):UnitedKingdom;2008to2021Source(s):OfficeforNationalStatistics(UK)NetcapitalexpenditureinthemanufactureofpharmaceuticalsintheUnitedKingdomfrom2008to2021,byindustrysubdivision(inmillionGBP)PharmaceuticalsmanufacturingexpenditureintheUK2008-2021,bysubdivisionManufactureofbasicpharmaceuticalpreparationsManufactureofbasicpharmaceuticalproducts1,4021,6001,4001,2001,000800706673675619590561600511430390367400324315317270279235177149142143200122961018374482008392009020102011201220132014201520162017201820192020202129Description:ThisstatisticdisplaysthenetcapitalexpenditureinthemanufactureofpharmaceuticalproductsandpharmaceuticalpreparationsintheUnitedKingdom(UK)from2008to2021,byindustrysubdivision.In2021,thenetexpenditureinthemanufactureofbasicpharmaceuticalproductswasvaluedat143millionBritishpounds.ReadmoreNote(s):UnitedKingdom;2008to2021Source(s):OfficeforNationalStatistics(UK)NetcapitalexpenditureinthemanufactureofpharmaceuticalproductsandpharmaceuticalpreparationsintheUKfrom2008to2021(inmillionGBP)Pharmaceuticalsmanufacturing:netcapitalexpenditureintheUK2008-20211,6001,4981,4001,2001,00080060040020001,0201,0238177747616095505055004734384414282008200920102011201220132014201520162017201820192020202130Description:Thisstatisticillustratesthetotalnetcapitalexpenditureinthemanufactureofpharmaceuticalproductsandpharmaceuticalpreparationsfrom2008to2021,intheUnitedKingdom.In2021,thenetcapitalexpenditurewasataround817millionBritishpounds.ReadmoreNote(s):UnitedKingdom;2008to2021Source(s):OfficeforNationalStatistics(UK)CHAPTER

05OTC(over-the-counter)Salesvalueofover-the-counter(OTC)medicinesinGreatBritainin2022,bymedicinecategory(inmillionsGBP)OTCmedicines:breakdownofsalesinGreatBritainbycategory2022SalesvalueinmillionGBP300

4000100200500600700800PainreliefCough/cold/sorethroatVitaminsandmineralsGastrointestinalSkintreatmentsSmokingcessationHayfeverremediesEyecare756.1572.4461.5350324.4232.6165.684Sleepingaids63.9Other20532Description:Thetotalsalesvalueofover-the-counter(OTC)drugsamountedto3.2billionBritishpoundsin2022.OTCreferstoaclassofmedicationthatcanbesoldwithouttheneedforaprescription.Painreliefgarneredthehighestsalesvalueatsome756millionBritishpounds,followedbycough,cold,andsorethroatremediesatsome572millionBritishpounds.ReadmoreNote(s):UnitedKingdom(GreatBritain)Source(s):Nielsen;ProprietaryAssociationofGreatBritainSalesvalueofOTCpainrelieftreatmentsinGreatBritainfrom2009to2022(inmillionGBP)OTCpainrelieftreatmentssalesvalueinGreatBritain2009-2022800700600756.1692.9658.5628.6581576.9566.4566.5542.9543.9530.3533.3532.7535.250040030020010002009201020112012201320142015201620172018201920202021202233/statistics/521802/otc-pain-relief-treatments-sales-value-great-britainThesalesvalueofover-the-counter(OTC)painrelieftreatmentsinGreatBritainwasapproximately756millionBritishpoundsin2022.Thiswasthehighestvalueintheprovidedtimeinterval,increasingbyaround36percentfromtheprecedingyear.

ReadmoreNote(s):UnitedKingdom(GreatBritain);2009to2022Source(s):Nielsen;ProprietaryAssociationofGreatBritainLeading10analgesicdrugsdispensedinEnglandin2022,bynumberofitemsLeading10analgesicdrugsdispensedinEngland2022,byitemNumberofitems02,000,000

4,000,000

6,000,000

8,000,000

10,000,000

12,000,000

14,000,000

16,000,000

18,000,000ParacetamolCo-codamol(Codeinephosphate/paracetamol)Tramadolhydrochloride16,168,04515,115,2495,660,406Codeinephosphate5,187,329Morphinesulfate5,111,163Buprenorphine2,505,4982,172,025SumatriptansuccinateOxycodonehydrochloride1,835,165Dihydrocodeinetartrate1,463,066Co-dydramol(Dihydrocodeine/paracetamol)1,431,04134Description:ThisstatisticdisplaystheleadingtenanalgesicdrugsdispensedinEnglandin2022,bynumberofprescriptionitems.Inthatyear,therewereapproximately16.2millionitemsofparacetamoldispensedinthecountry.ReadmoreNote(s):UnitedKingdom(England);2022Source(s):NHSBSASalesvalueofOTCcough,coldandsorethroattreatmentsinGreatBritainfrom2009to2022(inmillionGBP)Cough,coldandsorethroattreatmentsOTCsalesvalueinGreatBritain2009-2022700600500572.4478.7460.1452.2451.8447.2444437.1430.3420.6413.9415.1408.74003002001000344.42009201020112012201320142015201620172018201920202021202235Description:Thesalesvalueofover-the-counter(OTC)cough,coldandsorethroattreatmentsinGreatBritainstoodatover572millionBritishpoundsin2022.Thiswasthehighestvalueintheprovidedtimeintervalandrepresenteda36percentincreasecomparedtothepreviousyear.ReadmoreNote(s):UnitedKingdom(GreatBritain);2009to2022Source(s):Nielsen;ProprietaryAssociationofGreatBritainSalesvalueofvitaminsandmineralsinGreatBritainfrom2009to2022(inmillionGBP)VitaminsandmineralssalesvalueinGreatBritain2009-2022600500400495.2461.5453.7431.5427.1378372.9364353.9350.1345.9329.5324.4320.530020010002009201020112012201320142015201620172018201920202021202236Description:Thesalesvalueofover-the-countervitaminsandmineralsinGreatBritainwasaround461millionBritishpoundsin2022.Thiswasthethirdhighestvalueintheprovidedtimeintervalandrepresenteda1.6percentincreasecomparedtothepreviousyear.ThesalesvalueofOTCvitaminsandmineralshasgenerallyincreasedsince2009.ReadmoreNote(s):UnitedKingdom(GreatBritain);2009to2022Source(s):Nielsen;ProprietaryAssociationofGreatBritainCHAPTER

06DirectandindirectemploymentEmploymentinthebiopharmaceuticalsectorintheUnitedKingdomfrom2011to2021BiopharmaceuticalsectoremploymentintheUK2011-2021CorebiopharmaBiopharmaservice&supplychain66,30080,00069,40071,80064,50070,00060,00050,00040,00030,00020,00010,000066,00063,90064,90053,50064,00056,30063,80058,30064,00060,50062,90062,20061,40055,80050,40049,40047,80047,0002011201220132014201520162017201820192020202138Description:Thisst